Effects of Antifungal Treatment in COVID-19-Associated Pulmonary Aspergillosis: A European Multicenter Cohort Study
Related Experiment Video
Updated: Apr 21, 2026
Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
Florian Reizine1, Simon Feys2, Danila Seidel3
1Vannes Hospital Center, Vannes, France.
Background:
The management of COVID-19-associated invasive aspergillosis (CAPA) is still debated while cases continue to occur, and more and more frequently in vulnerable populations, stressing the importance of obtaining data on the treatment of this disease. Only small cohort studies and case reports have yet discussed this essential issue, and the data obtained are insufficient to make conclusions with confidence.
Research Question:
Is antifungal treatment associated with lower 60-day mortality in patients with probable or proven CAPA?
Study Design And Methods:
This study assessed the association of antifungal treatment with 60-day mortality for probable/proven CAPA cases from a French multicenter study and all consecutive CAPA cases (after 2020) from ICUs of 5 major European centers. Patients were compared according to antifungal treatment. Survival analysis was conducted by using Cox regression analysis and inverse probability of treatment weighting based on a propensity score.
Results:
In total, 259 patients with CAPA were included, 237 (91.5%) receiving antifungals for CAPA (215 [90.7%] of whom received azole antifungal drugs). Baseline characteristics were similar between patients who received antifungals and those who did not. Age (hazard ratio [HR], 1.02; 95% CI, 1.00-1.04; P = .048), immunosuppressive treatment (HR, 2.08; 95% CI, 1.12-3.41; P < .001), and remdesivir administration (HR, 1.96; 95% CI, 1.12-3.41; P = .018) were independently associated with increased 60-day mortality according to Cox regression analysis in the raw population. Male sex (HR, 0.61; 95% CI, 0.40-0.95; P = .024) and antifungal treatment (HR, 0.31; 95% CI, 0.17-0.59; P < .001) were associated with lower 60-day mortality. Cox-weighted regression showed lower 60-day mortality for patients receiving antifungals (weighted HR, 0.28; 95% CI, 0.13-0.58; P < .001.
Interpretation:
Our results show that antifungal treatment was associated with lower 60-day mortality in patients with CAPA. The high mortality rate observed in CAPA in immunocompromised patients and improved outcome for treated patients should encourage clinicians to actively screen for CAPA to enable rapid diagnosis and targeted treatment.
More Related Videos
12:29Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
Published on: April 19, 2017
15:01Confocal Laser Scanning Microscopy-Based Quantitative Analysis of Aspergillus fumigatus Conidia Distribution in Whole-Mount Optically Cleared Mouse Lung
Published on: September 18, 2021
Related Concept Videos
01:15Antifungal Agents
01:28Fungal Phylum Ascomycota
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: